What This Bill Does
The Advancing Menopause Care and Mid-Life Women’s Health Act would direct federal health agencies to expand research, public health promotion, provider training, and care coordination for perimenopause, menopause, and postmenopause. It focuses on women in mid-life and on conditions tied to menopausal symptoms, including mental health, cardiovascular issues, osteoporosis, sleep disorders, and genitourinary conditions. The bill authorizes $25 million per year for fiscal years 2027 through 2031 to carry out new NIH and HHS research activities. It also creates new grant programs, a public health dashboard, and training and outreach efforts aimed at improving diagnosis and treatment.
- Authorizes $25 million a year for fiscal years 2027 through 2031 for menopause and mid-life women’s health research.
- Directs NIH to expand research on perimenopause, menopause, and postmenopause through the Office of Research on Women’s Health.
- Creates grants for research on new treatments, diagnostic testing, and integrated care models.
- Requires HHS to establish a dashboard tracking menopausal symptoms and mid-life health outcomes.
- Adds public health promotion, care coordination, and training programs for early detection and treatment.
Who This Bill Affects
For the general public, this bill would mainly affect women in perimenopause, menopause, and postmenopause, along with clinicians, researchers, and public health agencies that serve them. It could increase access to research-backed care, training, and public health programs, and it authorizes $25 million annually from fiscal years 2027 through 2031 for related federal work. If you or someone in your household is navigating menopausal symptoms, the bill could eventually mean more evidence, more provider education, and more coordinated services.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Women experiencing menopause and mid-life symptoms Supporters would say the bill treats menopause as a real health issue rather than a private inconvenience. They would point to the bill’s focus on symptoms like hot flashes, sleep problems, mood disorders, and cognitive concerns, arguing that better research and care coordination could improve quality of life and reduce missed diagnoses.
- Clinicians and women’s health researchers Medical professionals and researchers may support the bill because it creates dedicated NIH and HHS research pathways, grants, and a data dashboard. They could argue that standardized research, translational work, and provider training would help turn scattered clinical experience into evidence-based care.
- Public health departments and safety-net providers Public health agencies and community providers may favor the bill because it offers grants for early detection, diagnosis, treatment, and care coordination. They could see it as a way to improve access for patients who face barriers to specialty care or who live in rural areas.
- Fiscal conservatives Some budget-minded critics may object to the new federal spending and the $25 million annual authorization. They may argue that the bill adds another specialized federal program and research agenda without clear evidence that Washington should lead this area.
- Skeptics of federal health program expansion Some opponents may say the bill broadens federal involvement into clinical practice, provider training, and public health promotion in a way that could duplicate existing HHS efforts. They may prefer that menopause care be handled through private medicine, state programs, or general women’s health initiatives rather than a new federal structure.
- Employers concerned about workplace mandates or guidance Because the bill directs research on workplace stressors related to severe menopausal symptoms and calls for public health recommendations, some employers may worry it could lead to new expectations around accommodations or workplace policy. They may support awareness but resist any downstream compliance costs or operational changes.
Key Implications
-
““authorize to be appropriated $25,000,000 for each of fiscal years 2027 through 2031””
This sets aside a specific federal funding stream for menopause and mid-life women’s health work over five fiscal years. In practice, it would support NIH and HHS research, grants, and related program activities if Congress later appropriates the money.
-
““establish and maintain a dashboard for the reporting of data on menopausal symptoms””
The bill would create a public-facing federal data tool tracking symptoms and health outcomes. That could make trends easier to monitor and could help researchers and policymakers see where care gaps are largest.
-
““award grants to eligible entities””
The bill opens the door to funding for states, public health departments, and accredited health education institutions. That means local and academic organizations could receive federal support to improve screening, diagnosis, treatment, and care coordination.
-
““expand research activities with respect to the severity and duration of perimenopausal, menopausal, and postmenopausal symptoms””
This would push federal health agencies to study not just whether symptoms exist, but how long they last and how severe they are. That matters because duration and severity affect treatment decisions, work life, and long-term health planning.
-
““develop recommendations and best practices to increase access to mental and behavioral health care services””
The bill links menopause to mental health and substance use prevention, not just hot flashes or reproductive symptoms. That could broaden the kinds of services women are screened for and referred to during mid-life care.
Latest Status
June 2, 2026
Referred to the House Committee on Energy and Commerce.
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.